Skip to main content
Erschienen in: Supportive Care in Cancer 8/2010

01.08.2010 | Editorial

Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities

verfasst von: Michael T. Brennan, Fred K. L. Spijkervet, Linda S. Elting

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Excerpt

The annual incidence of cancer in the world is estimated at more than 11 million cases with at least 1.3 million in the United States of America [1, 2]. Earlier cancer detection and advances in cancer therapies have provided important management advances to improve survival and quality of life. Common cancer treatment strategies include surgical resection, chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. The goal of such treatments is to cure the patient from the cancer. However, side effects from these therapies can limit the effectiveness of treatment and have a marked impact on the patient’s quality of life both during and after completion of the cancer therapy. The oral cavity is a common site of complications related to cancer therapies. The Surgeon General’s report on Oral Health in America estimates that more than 30–35% (400,000 annually) of patients undergoing cancer treatment will develop oral complications [3]. …
Literatur
1.
Zurück zum Zitat U.S. Cancer Statistics Working Group. United States cancer statistics: 2001 incidence and mortality. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (2004), pp 1–699 U.S. Cancer Statistics Working Group. United States cancer statistics: 2001 incidence and mortality. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (2004), pp 1–699
3.
Zurück zum Zitat U.S. Department of Health and Human Services. Oral Health in America: A Report of the Surgeon General, Executive Summary (2000) Rockville. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, MD U.S. Department of Health and Human Services. Oral Health in America: A Report of the Surgeon General, Executive Summary (2000) Rockville. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, MD
4.
Zurück zum Zitat Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMed Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMed
5.
Zurück zum Zitat Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMed Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMed
6.
Zurück zum Zitat Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen M, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598CrossRefPubMed Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen M, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598CrossRefPubMed
Metadaten
Titel
Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities
verfasst von
Michael T. Brennan
Fred K. L. Spijkervet
Linda S. Elting
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0855-4

Weitere Artikel der Ausgabe 8/2010

Supportive Care in Cancer 8/2010 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.